The Lonza Group has gained the approval of Swiss drug regulator Swissmedic to begin manufacturing Moderna Therapeutics' COVID-19 vaccine at a facility in Switzerland, according to the newspaper SonntagsZeitung. Swissmedic is expected to approve Moderna's COVID-19 vaccine soon following its approval of Pfizer and partner BioNTech's vaccine.
Lonza gains Swiss nod to start producing Moderna vaccine
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.